Log Out

OPKO Health (NASDAQ:OPK) Reaches New 52-Week Low at $1.83

Financial News Live · Sep 26, 2022 12:51

OPKO Health, Inc. (NASDAQ:OPK – Get Rating) hit a new 52-week low during trading on Monday . The stock traded as low as $1.83 and last traded at $1.83, with a volume of 24088 shares changing hands. The stock had previously closed at $1.88.

Analyst Upgrades and Downgrades

Separately, Piper Sandler lowered their price target on OPKO Health from $5.00 to $4.00 and set an "overweight" rating for the company in a research note on Friday, August 5th.

Get OPKO Health alerts:

OPKO Health Trading Down 4.3 %

The company has a fifty day moving average of $2.33 and a two-hundred day moving average of $2.76. The company has a current ratio of 2.30, a quick ratio of 1.91 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of -6.48 and a beta of 1.75.

OPKO Health (NASDAQ:OPK – Get Rating) last posted its earnings results on Thursday, August 4th. The biotechnology company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.02). OPKO Health had a negative return on equity of 7.72% and a negative net margin of 14.18%. The company had revenue of $309.90 million during the quarter, compared to analyst estimates of $326.87 million. During the same quarter last year, the firm posted ($0.03) earnings per share. The firm's revenue for the quarter was down 30.0% compared to the same quarter last year. On average, research analysts expect that OPKO Health, Inc. will post -0.38 EPS for the current year.

Insider Buying and Selling

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 50,000 shares of the business's stock in a transaction dated Friday, September 23rd. The stock was bought at an average cost of $1.85 per share, for a total transaction of $92,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 197,706,694 shares in the company, valued at $365,757,383.90. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders purchased 900,000 shares of company stock worth $2,008,000. 40.97% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of OPK. Cornerstone Advisory LLC bought a new stake in shares of OPKO Health during the fourth quarter valued at approximately $29,000. Aigen Investment Management LP bought a new stake in shares of OPKO Health during the second quarter valued at approximately $29,000. Verition Fund Management LLC bought a new stake in shares of OPKO Health during the second quarter valued at approximately $36,000. Humankind Investments LLC bought a new stake in shares of OPKO Health during the first quarter valued at approximately $37,000. Finally, Laurion Capital Management LP bought a new stake in OPKO Health in the second quarter valued at $38,000. 27.83% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Company Profile

(Get Rating)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.